biostudies-literatureBuyyounouski MKNCI NIH HHS584-591https://www.ebi.ac.uk/biostudies/studies/S-EPMC10941019biostudies-literatureUnknown10(5)<h4>Importance</h4>No prior trial has compared hypofractionated postprostatectomy radiotherapy (HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily treated with prostatectomy.<h4>Objective</h4>To determine if HYPORT is noninferior to COPORT for patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms at 2 years.<h4>Design, setting, and participants</h4>In this phase 3 randomized clinical trial, patients with a detectable prostate-specific antigen (PSA; ≥0.1 ng/mL) postprostatectomy with pT2/3pNX/0 disease or an undetectable PSA (<0.1 ng/mL) with either pT3 disease or pT2 disease with a positive surgical margin were recruited from 93 academic, community-based, and tertiary medical sites in the US and Canada. Between June 2017 and July 2018, JAMA oncologyNoninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.PMC10941019UG1 CA189867U24 CA180803U10 CA180868P30 CA093373U10 CA180822UG1 CA233340Schroeder TMPugh SLFeng FBuyyounouski MKMichalski JMBarkati MSandler HMMann MJVigneault EDuncan CEKonski AAValicenti RKMian OYMonitto DCChen RCLawton CAFHannan RKudchadker RJPotters LRodgers JPKittel JAfalseNoninferiority of Hypofractionated vs Conventional Postprostatectomy Radiotherapy for Genitourinary and Gastrointestinal Symptoms: The NRG-GU003 Phase 3 Randomized Clinical Trial.<h4>Importance</h4>No prior trial has compared hypofractionated postprostatectomy radiotherapy (HYPORT) to conventionally fractionated postprostatectomy (COPORT) in patients primarily treated with prostatectomy.<h4>Objective</h4>To determine if HYPORT is noninferior to COPORT for patient-reported genitourinary (GU) and gastrointestinal (GI) symptoms at 2 years.<h4>Design, setting, and participants</h4>In this phase 3 randomized clinical trial, patients with a detectable prostate-specific antigen (PSA; ≥0.1 ng/mL) postprostatectomy with pT2/3pNX/0 disease or an undetectable PSA (<0.1 ng/mL) with either pT3 disease or pT2 disease with a positive surgical margin were recruited from 93 academic, community-based, and tertiary medical sites in the US and Canada. Between June 2017 and July 2018, 2024-01-01T00:00:00Z2024 May2026-06-02T18:05:43.572Z2025-04-04T13:11:28.461ZS-EPMC109410193848341210.1001/jamaoncol.2023.7291